814 related articles for article (PubMed ID: 21898547)
1. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
[TBL] [Abstract][Full Text] [Related]
2. Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages.
Kim JL; Kang MK; Gong JH; Park SH; Han SY; Kang YH
Mol Nutr Food Res; 2012 Aug; 56(8):1223-33. PubMed ID: 22700286
[TBL] [Abstract][Full Text] [Related]
3. Osteogenic activity of silymarin through enhancement of alkaline phosphatase and osteocalcin in osteoblasts and tibia-fractured mice.
Kim JL; Park SH; Jeong D; Nam JS; Kang YH
Exp Biol Med (Maywood); 2012 Apr; 237(4):417-28. PubMed ID: 22496431
[TBL] [Abstract][Full Text] [Related]
4. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
[TBL] [Abstract][Full Text] [Related]
5. Osteogenic activity of yellow flag iris (Iris pseudacorus) extract modulating differentiation of osteoblasts and osteoclasts.
Kim JL; Li HM; Kim YH; Lee YJ; Shim JH; Lim SS; Kang YH
Am J Chin Med; 2012; 40(6):1289-305. PubMed ID: 23227798
[TBL] [Abstract][Full Text] [Related]
6. Antiosteoclastic activity of milk thistle extract after ovariectomy to suppress estrogen deficiency-induced osteoporosis.
Kim JL; Kim YH; Kang MK; Gong JH; Han SJ; Kang YH
Biomed Res Int; 2013; 2013():919374. PubMed ID: 23781510
[TBL] [Abstract][Full Text] [Related]
7. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
8. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
9. Antiosteoclastogenic activity of silicate-based materials antagonizing receptor activator for nuclear factor kappaB ligand-induced osteoclast differentiation of murine marcophages.
Hung CJ; Kao CT; Chen YJ; Shie MY; Huang TH
J Endod; 2013 Dec; 39(12):1557-61. PubMed ID: 24238446
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
11. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
Gong W; Dou H; Liu X; Sun L; Hou Y
Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts.
Zhang F; Tanaka H; Kawato T; Kitami S; Nakai K; Motohashi M; Suzuki N; Wang CL; Ochiai K; Isokawa K; Maeno M
Biochimie; 2011 Feb; 93(2):296-305. PubMed ID: 20937352
[TBL] [Abstract][Full Text] [Related]
13. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
14. Coumarin Ameliorates Impaired Bone Turnover by Inhibiting the Formation of Advanced Glycation End Products in Diabetic Osteoblasts and Osteoclasts.
Lee EJ; Kang MK; Kim YH; Kim DY; Oh H; Kim SI; Oh SY; Na W; Kang YH
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32679814
[TBL] [Abstract][Full Text] [Related]
15. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.
Xu F; Dong Y; Huang X; Chen P; Guo F; Chen A; Huang S
Mol Med Rep; 2016 Sep; 14(3):2289-96. PubMed ID: 27430581
[TBL] [Abstract][Full Text] [Related]
17. DOK3 Modulates Bone Remodeling by Negatively Regulating Osteoclastogenesis and Positively Regulating Osteoblastogenesis.
Cai X; Xing J; Long CL; Peng Q; Humphrey MB
J Bone Miner Res; 2017 Nov; 32(11):2207-2218. PubMed ID: 28650106
[TBL] [Abstract][Full Text] [Related]
18. Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts.
Zhang T; Han W; Zhao K; Yang W; Lu X; Jia Y; Qin A; Qian Y
FASEB J; 2019 Apr; 33(4):5399-5410. PubMed ID: 30702934
[TBL] [Abstract][Full Text] [Related]
19. Effects of JSOG-6 on protection against bone loss in ovariectomized mice through regulation of osteoblast differentiation and osteoclast formation.
Chung HJ; Cho L; Shin JS; Lee J; Ha IH; Park HJ; Lee SK
BMC Complement Altern Med; 2014 Jun; 14():184. PubMed ID: 24903150
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
